The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD. The biobank contains biomaterial (PBMCs, cfDNA and PAXgene) and clinical data from patients with metastatic UC in whom treatment with anti-PD-(L)1 has been initiated.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
One year since the new business model for the Radboud Biobank was implemented
3 March 2026The new business model was introduced last year, with departments paying half of the biomaterial processing costs, covering the storage costs, and applying a graduated rate for sample issuance.
go to page
Periodic invoicing biobank collections
3 March 2026Since 2025, the Radboud Biobank periodically charges all biobank collections for the processing and storage costs incurred.
go to page
The purpose of a central biobank facility such as the Radboud Biobank
3 March 2026As the central biobank facility of Radboudumc, the Radboud Biobank does more than simply store human biomaterials.
go to page
Radboud Biobank's 2025 annual report
3 March 2026The Radboud Biobank's 2025 annual report is now available on request.
go to page
Aevai Health developed a virtual assistant
3 March 2026Aevai Health has developed Alva - a virtual assistant to engage research participants, which can support participants with health literacy, understanding research protocols, and with using measurement devices.
go to page
Radboudumc Researchers Highlight Critical Gaps in Reporting Pre-Analytical Processes in Biobanked Biomaterials
21 October 2025Radboudumc Researchers have identified significant shortcomings in pre-analytical sample processing reporting in clinical biomarker research, a factor crucial for study reliability and replicability.
go to page